Dominic Muston

1.2k total citations · 1 hit paper
25 papers, 923 citations indexed

About

Dominic Muston is a scholar working on Oncology, Economics and Econometrics and Ophthalmology. According to data from OpenAlex, Dominic Muston has authored 25 papers receiving a total of 923 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 7 papers in Economics and Econometrics and 5 papers in Ophthalmology. Recurrent topics in Dominic Muston's work include PARP inhibition in cancer therapy (7 papers), Economic and Financial Impacts of Cancer (6 papers) and Retinal Diseases and Treatments (5 papers). Dominic Muston is often cited by papers focused on PARP inhibition in cancer therapy (7 papers), Economic and Financial Impacts of Cancer (6 papers) and Retinal Diseases and Treatments (5 papers). Dominic Muston collaborates with scholars based in United States, United Kingdom and France. Dominic Muston's co-authors include David Weinstein, Christopher R. Chapple, Vik Khullar, Caty Ebel Bitoun, Zahava Gabriel, J Melia, Chris Parker, David P. Dearnaley, Sue Moss and Anthony M. Downs and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and British Journal of Cancer.

In The Last Decade

Dominic Muston

24 papers receiving 887 citations

Hit Papers

1 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Effects of Antimuscarinic Treatments in Overactive Bladder: An Update of a Systematic Review and Meta-Analysis

2008 601 citations Christopher R. Chapple, Vik Khullar et al. European Urology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Dominic Muston United States	10	574	481	389	147	119	25	923
M. Hehir United Kingdom	16	522 0.9×	383 0.8×	94 0.2×	640 4.4×	180 1.5×	28	1.0k
Myong Kim South Korea	20	460 0.8×	320 0.7×	294 0.8×	528 3.6×	347 2.9×	79	1.3k
Antonio Cicione Italy	20	400 0.7×	214 0.4×	132 0.3×	472 3.2×	431 3.6×	88	1.1k
F. Rocco Italy	11	259 0.5×	237 0.5×	58 0.1×	536 3.6×	181 1.5×	34	759
Francesco Aragona Italy	15	188 0.3×	212 0.4×	46 0.1×	558 3.8×	333 2.8×	46	942
M. Raschid Hoda Germany	17	136 0.2×	153 0.3×	119 0.3×	454 3.1×	323 2.7×	45	899
Osamu Kamihira Japan	16	179 0.3×	193 0.4×	35 0.1×	607 4.1×	455 3.8×	65	1.1k
William D. Belville United States	17	486 0.8×	448 0.9×	129 0.3×	383 2.6×	244 2.1×	44	879
P. Destefanis Italy	19	353 0.6×	128 0.3×	30 0.1×	395 2.7×	455 3.8×	64	1.1k
Yaron Ehrlich Israel	16	49 0.1×	117 0.2×	88 0.2×	354 2.4×	424 3.6×	37	711

Countries citing papers authored by Dominic Muston

Since Specialization

Citations

This map shows the geographic impact of Dominic Muston's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dominic Muston with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dominic Muston more than expected).

Fields of papers citing papers by Dominic Muston

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dominic Muston. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dominic Muston. The network helps show where Dominic Muston may publish in the future.

Co-authorship network of co-authors of Dominic Muston

This figure shows the co-authorship network connecting the top 25 collaborators of Dominic Muston. A scholar is included among the top collaborators of Dominic Muston based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dominic Muston. Dominic Muston is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Monk, Bradley J., et al.. (2024). Cost-Effectiveness of Pembrolizumab as First-Line Treatment in Patients with Persistent, Recurrent, or Metastatic Cervical Cancer in the United States. Oncology and Therapy. 13(1). 85–98. 5 indexed citations

Lin, Fan, et al.. (2024). Modeling health outcomes associated with BRCA testing and treatment strategies for patients with metastatic pancreatic cancer. Pancreatology. 24(2). 271–278. 1 indexed citations

Muston, Dominic. (2024). Informing Structural Assumptions for Three State Oncology Cost-Effectiveness Models through Model Efficiency and Fit. Applied Health Economics and Health Policy. 22(5). 619–628. 2 indexed citations

Muston, Dominic, et al.. (2023). Cost-Effectiveness Analysis of Biomarker Testing to Guide First-Line PARP Inhibitor Maintenance for Patients with Advanced Ovarian Cancer After Response to First-Line Platinum Chemotherapy in the USA. Targeted Oncology. 18(4). 531–541. 1 indexed citations

Lin, Fan, et al.. (2022). Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer. PharmacoEconomics - Open. 6(6). 811–822. 7 indexed citations

Evans, Rachel, Neil Hawkins, Dominic Muston, et al.. (2021). Exploring the Impact of Treatment Switching on Overall Survival from the PROfound Study in Homologous Recombination Repair (HRR)-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC). Targeted Oncology. 16(5). 613–623. 5 indexed citations

Agarwal, Neeraj, Keith R. Abrams, Dominic Muston, et al.. (2020). 622P Exploring the impact of treatment switching on the interim overall survival (OS) results of the PROfound study. Annals of Oncology. 31. S514–S514. 1 indexed citations

Muston, Dominic, Robert Hettle, Matthew Monberg, et al.. (2020). Cost-effectiveness of olaparib as a maintenance treatment for women with newly diagnosed advanced ovarian cancer and BRCA1/2 mutations in the United States. Gynecologic Oncology. 159(2). 491–497. 16 indexed citations

Gao, Wei, Dominic Muston, Matthew Monberg, et al.. (2020). A Critical Appraisal and Recommendations for Cost-Effectiveness Studies of Poly(ADP-Ribose) Polymerase Inhibitors in Advanced Ovarian Cancer. PharmacoEconomics. 38(11). 1201–1218. 5 indexed citations

10.

Mistry, Rohit, et al.. (2019). PCN96 US COST-EFFECTIVENESS OF PEMBROLIZUMAB COMPARED TO REGORAFENIB AND CABOZANTINIB IN SECOND LINE TREATMENT OF ADVANCED HEPATOCELLULAR CARCINOMA. Value in Health. 22. S73–S74. 1 indexed citations

11.

Cunha‐Vaz, José, Michael Ulbig, Ian Pearce, et al.. (2018). A noninterventional study to monitor patients with diabetic macular oedema starting treatment with ranibizumab (POLARIS). Acta Ophthalmologica. 96(8). e942–e949. 22 indexed citations

12.

Muston, Dominic, et al.. (2018). An efficacy comparison of anti-vascular growth factor agents and laser photocoagulation in diabetic macular edema: a network meta-analysis incorporating individual patient-level data. BMC Ophthalmology. 18(1). 340–340. 8 indexed citations

13.

Brazier, John, Dominic Muston, G. Sarah Power, et al.. (2017). Evaluating the Relationship Between Visual Acuity and Utilities in Patients With Diabetic Macular Edema Enrolled in Intravitreal Aflibercept Studies. Investigative Ophthalmology & Visual Science. 58(11). 4818–4818. 15 indexed citations

14.

Bamber, Luke, et al.. (2015). Cost-effectiveness analysis of treatment of venous thromboembolism with rivaroxaban compared with combined low molecular weight heparin/vitamin K antagonist. Thrombosis Journal. 13(1). 20–20. 33 indexed citations

15.

Korobelnik, Jean‐François, Jos Kleijnen, Shona Lang, et al.. (2015). Systematic review and mixed treatment comparison of intravitreal aflibercept with other therapies for diabetic macular edema (DME). BMC Ophthalmology. 15(1). 52–52. 25 indexed citations

16.

McLeod, Euan, et al.. (2015). Cost of Illness, Diagnosis and treatment patterns for Diabetic Macular Edema across 13 Countries. Value in Health. 18(3). A181–A181. 1 indexed citations

17.

Amelio, Justyna, et al.. (2014). Prevalence of gastrointestinal stromal tumour (GIST) in the United Kingdom at different therapeutic lines: an epidemiologic model. BMC Cancer. 14(1). 364–364. 15 indexed citations

18.

Lee, David, et al.. (2010). Cost Effectiveness of CT Colonography for UK NHS Colorectal Cancer Screening of Asymptomatic Adults Aged 60–69 Years. Applied Health Economics and Health Policy. 8(3). 141–154. 31 indexed citations

19.

Chapple, Christopher R., Vik Khullar, Zahava Gabriel, et al.. (2008). The Effects of Antimuscarinic Treatments in Overactive Bladder: An Update of a Systematic Review and Meta-Analysis. European Urology. 54(3). 543–562. 601 indexed citations breakdown →

20.

Parker, Chris, Dominic Muston, J Melia, Sue Moss, & David P. Dearnaley. (2006). A model of the natural history of screen-detected prostate cancer, and the effect of radical treatment on overall survival. British Journal of Cancer. 94(10). 1361–1368. 98 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact